on MEDIAN TECHNOLOGIES (EPA:ALMDT)
Median Technologies unveils its 2024 financial results and its 2025 outlook
On January 31, 2025, Median Technologies published its financial indicators for 2024 and its outlook for 2025. Revenue for the past year amounted to €22.9 million, recording an increase of 3.3% compared to 2023. The order book reached €71.0 million at the end of the year.
Median expects to submit regulatory filings for eyonis™ LCS, an AI medical device for lung cancer screening, in the second quarter of 2025. FDA approval is expected in the third quarter of the same year. Commercialization is expected to begin in the United States shortly thereafter.
The company has strengthened its cash position with an extended loan agreement with the EIB and new financing with Iris. These initiatives extend the cash horizon to the end of 2025.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDIAN TECHNOLOGIES news